Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. A study showed that using Taltz with Zepbound worked better than Taltz alone for adults with psoriasis and obesity. Eli Lilly signed a licensing deal with CSL Limited for clazakizumab, an anti-IL-6 monoclonal antibody. Lilly will pay $100 million upfront and additional milestone payments. The company develops treatments in various therapeutic areas. For more investment opportunities, consider AI stocks or alternative energy and infrastructure stocks. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal